Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 31, 2026 -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 25
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SWIFT Drops Bombshell Statement About Ripple (XRP)
ETH at $2,179: $1.056B in Short Liquidations Could Trigger Cascade

Is NEAR Protocol’s 60% Rally Just Getting Started?

Is BSB Price Preparing For A Push Toward $2?

